Canadian Pharmacists Association’s Post

💊 Understanding the BIOSECURE Act: A New Chapter in Biopharma Security 🧪 The recent House passage of the BIOSECURE Act reflects growing concerns over national security and biopharma supply chains. Targeting key Chinese companies, the bill aims to curb U.S. biopharma's dependency on foreign entities. While seen as essential for safeguarding American healthcare data, critics argue it could disrupt drug supply chains and clinical trials. As the bill moves to the Senate, the debate highlights a critical intersection of national security and global pharma collaboration. Stay tuned for further Senate developments. #Biopharma #NationalSecurity #BIOSECUREAct #SupplyChain

Is your market access strategy aligned with the realities of 2025? Join Verpora’s Global Innovative Contracting Webinar on Thursday, 16th January 2025, to stay ahead of the latest shifts in market access and innovative contracting. In this video, Omar Ali and Adam Buckler break down what to expect: 🔹 Real-world case studies on the latest models shaping life science contracting globally 🔹 Payer perspectives on value-based agreements and pricing strategies 🔹 The latest policy changes in your region If market access is part of your 2025 strategy, this session is not to be missed. 📅 Date: Thursday, 16 January 2025 🕒 Sessions Available: Session 1 - UK/EU/Asia: 08:30 GMT (09:30 Europe) Session 2 - US/LATAM: 16:30 GMT (11:30 EST / 10:30 CST / 08:30 PST) 👉 Register now – link in the comments. #MarketAccess #InnovativeContracting #Pharma #Webinar #Verpora

Less than a week to go until our first Global Innovative Contracting Webinar of 2025. I'm very interested to understand more about multi-indication and tiered-pricing models, which my colleagues will be discussing with real-world examples!

Last chance to register for Thursday’s unmissable webinar.   This week, we’ll be diving into real-world examples of innovative contracting shaping market access strategies around the globe.   I’ll be discussing key developments in the US, including how payers are addressing access challenges with GLP-1 therapies, and a unique value-and-financial-based agreement crafted by a PBM. I’ll also unpack a fascinating Medicaid agreement for Dupixent in Colorado, and what we might learn by looking beyond the US.   Meanwhile, with my colleague Adam Buckler, we will also cover exciting trends from Europe, including the UK’s bold move to incentivize antimicrobial innovation with a subscription model and Roche’s tiered pricing strategy in Denmark for SMA treatment.   If you’re working in market access or pricing, this session is packed with insights you can’t afford to miss. 📅 Thursday, 16th January ⏰ Sessions for Eastern and Western Timezones 💻 Register now – link in the comments.   #InnovativeContracting #MarketAccess #Pharma 

▶️ Missed the March video review? We talked about the progress of our hospitals' deployments, the repurposing of drugs, and more hot topics! It's ok, you can still catch up Galeon's latest news here, tune in! 🔗 https://lnkd.in/ecNb6MPM

Expect these 5 stages During Drug Recovery: 1. pre-contemplation 2. contemplation 3. preparation 4. action 5. maintenance Read the blog here: https://zurl.co/VszM #RenewedHope #RecoveryPath #HealingTogether #AddictionRecovery #BrighterTomorrow

I am happy to partner with the great people at Pharmacy U! Here is my latest blog.

The Global Drug Survey 2024 is live. To take part in this anonymous and confidential survey about drug use please use the link below. The aim of the survey is to make drug use safe. https://lnkd.in/g9rKswN #GDS2024 #harmreduction

This past week we have been counting down the Top 3 Drug Searches on DRUGDOCS® in 2024.   It’s no surprise that Ozempic takes the #1 spot as the most-searched drug on DRUGDOCS®.   In 2024, Ozempic continued to make waves in healthcare, with growing off-label use for weight loss sparking both excitement and ethical debates. Amid its popularity, concerns about accessibility, affordability, additional indications, and the need for long-term safety studies highlight critical challenges for the future of GLP-1 therapies.   Find the clinical evidence for #Ozempic at DRUGDOCS®: https://lnkd.in/gjy4C8QW